Signal12

Exciting milestone alert! Signal12 today announced the alignment of our Phase 3 clinical trial strategy for Pro-ocular? with the U.S. Food and Drug Administration (FDA). Pro-ocular? is a novel, drop-free therapy poised to revolutionize the treatment of ocular Graft-versus-Host Disease (oGvHD). ? This key regulatory milestone, achieved following a highly productive Type C meeting, sets the stage for Signal12's transformative Phase 3?clinical research in an area of high unmet medical need.

Navigating the complexities of ocular Graft-versus-Host Disease (oGVHD) requires a comprehensive understanding of both current diagnostic tools and the potential of future advancements. We dive into the diagnostic challenges associated with oGVHD, highlighting the limitations of today's tools and outlining promising directions for future research and clinical practice. If you're interested in learing more about the evolving landscape of oGvHD diagnosis and the innovative approaches on the horizon, read our blog post at the link below. #oGvHD #ocularhealth https://lnkd.in/eeMhnJbS

Delve into the pathophysiology and clinical implications of ocular graft-versus-host disease (oGVHD). Our comprehensive analysis discusses how oGVHD affects the eyes, emphasizing the importance of early detection and targeted treatment strategies to improve patient outcomes. #ocularhealth #oGvHD

Prescription eye drops for treating Dry Eye Disease have a slow onset of action, with the market leader taking 180 days to show effectiveness. Our patented, first-of-its-kind drug, Pro-ocular, which is applied to the forehead, provides noticeable relief in less than 14 days, offering a faster path to comfort. Learn more at the link below.

The global?dry eye?syndrome?market?size was valued at $7.02 billion in 2023 & is projected to grow from $7.49 billion in 2024 to $13 billion by 2032. ?? #DryEyeDisease #RaisingCapital #Phase3 #OcularHealth #ProOcular

Eye drop product recalls can happen due to contamination or harmful ingredients. Always stay informed by checking recall notices from reputable sources like the FDA. #EyeHealth #ProductSafety #DryEyeDisease

??Spotlight on Leadership?? Meet Tom Mitro, CEO of Signal12, who brings over 30 years of pharmaceutical industry expertise to our team. Before joining us, Tom served as President & COO of Aerie Pharmaceuticals, where he drove the company’s annual sales to over $100 million, leading to its successful acquisition by Alcon. His leadership prowess was also evident at ISTA Pharmaceuticals, where he initiated and led commercialization efforts, growing its sales to over $165 million annually. With 24 years of experience at Allergan in multiple leadership roles, Tom's track record speaks for itself. Under Tom’s guidance, Signal12 is poised for groundbreaking achievements in ocular health for the treatment of dry eye disease. We’re excited to embark on this journey of innovation and growth with such an accomplished leader at the helm. #Leadership #OcularHealth #Innovation #Pharmaceuticals #Healthcare #Signal12 #DryEyeDisease

Screen Time and Dry Eye: Excessive screen time is a leading cause of dry eye disease. The 20-20-20 rule (taking a 20-second break every 20 minutes to look at something 20 feet away) can help reduce strain. #DigitalEyeStrain #HealthyEyes

Did you know that certain medications, such as antihistamines and antidepressants, can contribute to dry eye? Discuss options with your healthcare provider if you experience symptoms. #MedicationAwareness #DryEyeDisease ??

“I am honored to lead Signal12 in its mission to transform the landscape of ocular health. The company’s pioneering technology and impressive clinical data for Pro-ocular make it a game-changer in treating dry eye disease. I am eager to leverage our team’s extensive experience and push forward with our Phase 3 trials. The eye health market is ripe for innovation, and Signal12 will play a crucial role in addressing unmet needs and improving the lives of millions affected by ocular conditions.” - Tom Mitro, President & CEO